<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03014115</url>
  </required_header>
  <id_info>
    <org_study_id>2015-1080</org_study_id>
    <nct_id>NCT03014115</nct_id>
  </id_info>
  <brief_title>Effects of Different ARA Formulations of Infant Formula on Fatty Acid Status, Immune Markers and Infection Rates in Infants</brief_title>
  <official_title>EFFECTS OF DIFFERENT ARA FORMULATIONS OF INFANT FORMULA ON FATTY ACID STATUS, IMMUNE MARKERS AND INFECTION RATES IN INFANTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DSM Nutritional Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SynteractHCR</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>DSM Nutritional Products, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical trial will investigate the effect of different formulations of ARA + 0.4% DHA in
      infant formula on plasma fatty acid status in healthy 6 months old infants supplemented for 6
      months. A 6-month follow on phase will provide additional efficacy (e.g. infection rates,
      immune markers) and safety information in these 12-18 month old infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, parallel-group study of 0% ARA +0.4% DHA or 0.76%
      ARA +0.4% DHA supplemented infant formula provided to 6 months old healthy infants for 6
      months. Infants will have been breast-fed or formula-fed prior to enrollment. The difference
      in total plasma fatty acid ARA levels between the two groups at 6 months of supplementation
      will be measured. Parents will be asked about the infant's current daily diet (fatty acid
      intakes calculated via 24 hour recalls). All completed infants will be enrolled into a 6
      month extension period (non-supplemented) to collect additional measures of efficacy (i.e.
      infections and illnesses, immune markers) and safety out to 18 months of age.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>total plasma fatty acid ARA levels</measure>
    <time_frame>6 months of supplementation</time_frame>
    <description>difference in total plasma fatty acid ARA levels between the two groups at 6 months of supplementation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of infections</measure>
    <time_frame>6 months of supplementation</time_frame>
    <description>record number, type and duration of infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight gain</measure>
    <time_frame>6 months of supplementation</time_frame>
    <description>differences between groups in weight gain (kg/d)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length gain</measure>
    <time_frame>6 months of supplementation</time_frame>
    <description>differences between groups in length gain (cm/d)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>head circumference</measure>
    <time_frame>6 months of supplementation</time_frame>
    <description>differences between groups in head circumference (cm/d)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dietary intake of ARA</measure>
    <time_frame>6 months of supplementation</time_frame>
    <description>24 hour recall questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma levels of immune markers</measure>
    <time_frame>6 months of supplementation</time_frame>
    <description>cytokines and T cells levels in plasma will be measured</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Healthy Infants</condition>
  <arm_group>
    <arm_group_label>combination ARA+ DHA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>combination 0.76% ARA+ 0.4% DHA in infant formula per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DHA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0% ARA +0.4% DHA in infant formula per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>combination ARA + DHA</intervention_name>
    <description>combination ARA + DHA supplemented infant formula</description>
    <arm_group_label>combination ARA+ DHA</arm_group_label>
    <other_name>infant formula</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>DHA</intervention_name>
    <description>DHA supplemented infant formula</description>
    <arm_group_label>DHA</arm_group_label>
    <other_name>infant formula</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  singleton infants,

          -  parent of legal age to consent,

          -  willing to feed the child the assigned study formula for the treatment duration,

          -  parent agrees to scheduled blood draws

        Exclusion Criteria:

          -  exclusively breastfed or formula-fed beyond 6 months,

          -  difficulty swallowing or other congenital malformation or metabolic anomaly,

          -  taking omega-3 (supplemented) foods,

          -  mother had gestational diabetes or is Type II diabetic,

          -  born at &lt;37 weeks gestational age,

          -  participating in another study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Weeks</minimum_age>
    <maximum_age>26 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ascension Marcos, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICTAN</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Esteras</last_name>
    <email>laura.esteras@synteracthcr.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Carme Montero, PhD</last_name>
    <email>maria-carme.montero@synteracthcr.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro de Salud Aravaca</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Diaz González, MD</last_name>
      <email>cdiazglez@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Salud Arganda del Rey</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Sánchez Bustos, MD</last_name>
      <email>pilarsanchezbustos@yahoo.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2017</study_first_submitted>
  <study_first_submitted_qc>January 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2017</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>arachidonic</keyword>
  <keyword>docosahexaenoic acid</keyword>
  <keyword>infant formula</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

